Advances in the pharmacology of cyclooxygenase

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药理学第二研究室

	Advances in the pharmacology of cyclooxygenase
	Zhang Weiyu; Zhu Xingzu
刊名	Chinese Bulletin of Life Sciences
	2005
卷号	17 期号:3 页码:230-235
关键词	cyclooxygenase prostaglandins inflammation neurodegenerative disease cardiovascular disease cancer non-steroidal anti-inflammatory drugs
ISSN号	1004-0374
其他题名	环加氧酶及其药理学研究进展
文献子类	Article
英文摘要	Cyclooxygenase (COX), a rate-limited enzyme in arachidonic acid metabolic pathways, can catalyse the synthesis of cyclic endoperoxides from arachidonic acid to form prostaglandins (PGs). Two cyclooxygenase isoforms have been identified and referred to as constitutive COX-1 and inducible COX-2. According to a popular hypothesis, COX-1 generates "good" prostaglandins for physiological housekeeping functions, while COX-2 forms the "bad" prostaglandins responsible for inflammatory symptoms. However, recent data show that the biological functions of prostanoids formed by the two enzymes are much more complex and interrelated than previously appreciated. The objective of the article is to provide an overview of recent developments in the field about the role of COX in various diseases, and to discuss the feasibility as a potential target for therapeutic treatment.
资助项目	上海市生命科学重大基础研究项目[00000000]
WOS研究方向	Biochemistry & Molecular Biology (provided by Clarivate Analytics)
语种	中文
CSCD记录号	CSCD:1966835
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/268345]
专题	药理学第二研究室
作者单位	Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Graduate School of CAS, Shanghai 201203, China.
推荐引用方式 GB/T 7714	Zhang Weiyu,Zhu Xingzu. Advances in the pharmacology of cyclooxygenase[J]. Chinese Bulletin of Life Sciences,2005,17(3):230-235.
APA	Zhang Weiyu,&Zhu Xingzu.(2005).Advances in the pharmacology of cyclooxygenase.Chinese Bulletin of Life Sciences,17(3),230-235.
MLA	Zhang Weiyu,et al."Advances in the pharmacology of cyclooxygenase".Chinese Bulletin of Life Sciences 17.3(2005):230-235.